Actively Recruiting
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
Led by Peking University Third Hospital · Updated on 2026-01-02
140
Participants Needed
4
Research Sites
122 weeks
Total Duration
On this page
Sponsors
P
Peking University Third Hospital
Lead Sponsor
P
Peking University First Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.
CONDITIONS
Official Title
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Signed informed consent form
- Females must not plan pregnancy or oocyte donation from screening until 1 week after last dose and must use highly effective physical contraception
- Males must not plan fertility or sperm donation during the same period and must use highly effective physical contraception
- Acceptable contraception methods include barrier methods, intrauterine devices or systems, surgical sterilization performed at least 6 months prior, or other investigator-confirmed methods
You will not qualify if you...
- Allergy to Brivudine, Famciclovir, or Penciclovir
- Current use of fluorouracil agents such as 5-fluorouracil, capecitabine, tegafur, or flucytosine
- Cancer patients currently undergoing chemotherapy
- Pregnant or lactating women
- Parkinson's disease
- Any condition deemed inappropriate for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Peking University Third Hospital
Beijing, China, 100191
Actively Recruiting
2
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Beijing, China
Actively Recruiting
3
Peking University First Hospital
Beijing, China
Actively Recruiting
4
Xuanwu Hospital, Capital Medical University
Beijing, China
Not Yet Recruiting
Research Team
J
Jin-Zhu Guo, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here